NEXGEL Reports Third Quarter 2025 Financial Results

Core Viewpoint - NEXGEL, Inc. reported flat revenue year-over-year for Q3 2025, but showed improvement in Adjusted EBITDA loss, indicating operational efficiencies and growth in contract manufacturing and consumer branded products [3][4][8]. Financial Performance - Revenue for Q3 2025 was $2.93 million, a slight decrease of 0.20% from $2.94 million in Q3 2024 [4][10]. - Cost of revenues decreased to $1.69 million from $1.79 million in Q3 2024, attributed to lower material costs and reduced amortization and depreciation [5][10]. - Gross profit increased to $1.24 million, with a gross profit margin of 42.4%, up from 39.3% in Q3 2024 [6][10]. - Selling, general and administrative expenses rose slightly to $1.96 million from $1.94 million in Q3 2024, mainly due to increased compensation and consulting fees [7][10]. - Net loss attributable to NEXGEL stockholders was $0.65 million, an improvement from a net loss of $0.69 million in Q3 2024 [8][10]. Operational Highlights - The company experienced stable performance in contract manufacturing and branded products, with growth driven by partnerships and new customer onboarding [3][4]. - NEXGEL's consumer brands are gaining traction through new product launches in beauty and skincare [3]. Cash Position - As of September 30, 2025, NEXGEL had a cash balance of approximately $938 thousand and a restricted cash balance of $920 thousand, supported by $1 million in non-dilutive capital from STADA [9][10]. Shareholder Information - As of November 11, 2025, NEXGEL had 8,143,133 shares of common stock outstanding [9].